
Sign up to save your podcasts
Or


Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.
By Keyvan Koushan, MD, FRCSC4.4
1111 ratings
Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.

43 Listeners

18 Listeners

97 Listeners

5 Listeners

4 Listeners

8 Listeners

22 Listeners

52 Listeners

10 Listeners

16 Listeners

18 Listeners

0 Listeners

1 Listeners

19 Listeners

0 Listeners